Coating of fast absorption or dissolution

Abstract

A coating of fast absorption or fast dissolution on an implantable device and methods of making and using of the coating are provided.

1 . A coating on an implantable device, the coating comprising
 a soluble or fast absorption polymer or material, and   between about 1% and about 20% of a low molecular weight polymer,   wherein the low molecular weight polymer has a weight-average weight (M w ) below 5,000 Daltons and is hydrophilic, and   wherein the coating has a thickness from about 1 μm to about 100 μm and about 50 wt % or more of the coating can absorb or dissolve within 24 hours after implantation.   
     
     
         2 . (canceled) 
     
     
         3 . The coating of  claim 1 , wherein the low molecular weight polymer comprises acidic or basic pendant groups. 
     
     
         4 . The coating of  claim 1 , wherein the soluble or fast absorption polymer or material comprises an ionic or non-ionic polymer. 
     
     
         5 . The coating of  claim 1 , wherein the soluble or fast absorption polymer or material comprises poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), hyaluronic acid, hydroxyl cellulose, CMC (carboxymethyl cellulose), hydroxy propyl methyl cellulose (HPMC), hydroxy propyl methacrylamide (HPMA), poly(butylene terephthalate-co-poly(ethylene glycol) (PBT-PEG), poly(butylene terephthalate-co-carboxy methyl cellulose) (PBT-co-CMC), polysaccharide, phosphoryl choline polymer, chitosan, collagen, PLA, PLGA, PEA, polyacylate, polymethacrylate or a combination thereof. 
     
     
         6 . The coating of  claim 1 , wherein the soluble or fast absorption polymer or material has a M w  of 10,000 Daltons to about 150,000 Daltons. 
     
     
         7 . (canceled) 
     
     
         8 . The coating of  claim 1  wherein the soluble or fast absorption polymer comprises a phosphoryl choline polymer. 
     
     
         9 . The coating of  claim 8 , wherein the phosphoryl choline polymer comprises units derived from a vinyl monomer comprising phosphoryl choline. 
     
     
         10 . The coating of  claim 8 , wherein phosphoryl choline polymer has the formula of 
       
         
           
           
               
               
           
         
       
       where n and m independently range from about 0.01 to about 0.99. 
     
     
         11 . The coating of  claim 10  where some or all butyl groups can be replaced by methyl, ethyl, other alkyl groups, or a combination thereof. 
     
     
         12 . The coating of  claim 11 , wherein n and m are about 0.5. 
     
     
         13 . The coating of  claim 10 , wherein the phosphoryl choline polymer is random or block copolymer. 
     
     
         14 . The coating of  claim 11 , wherein the phosphoryl choline polymer is a random or block copolymer. 
     
     
         15 . The coating of  claim 12 , wherein the phosphoryl choline polymer is a random or block copolymer. 
     
     
         16 . The coating of  claim 8 , wherein the phosphoryl choline polymer comprises at least one phosphoryl choline moiety and at least one moiety derived from a biocompatible polymer. 
     
     
         17 . The coating of  claim 16 , wherein the biocompatible polymer comprises poly(ester amide), poly(lactic acid), poly(glycolic acid), poly(caprolactone), poly(dioxanone), or poly(ester amide-2,2,6,6-tetramethyl-1-piperidinyloxy) (PEA-TEMPO). 
     
     
         18 . The coating of  claim 1 , wherein the implantable device is stent. 
     
     
         19 . The coating of  claim 8 , wherein the implantable device is stent. 
     
     
         20 . The coating of  claim 1 , further comprising a bioactive agent. 
     
     
         21 . The coating of  claim 8 , further comprising a bioactive agent. 
     
     
         22 . The coating of  claim 1 , further comprising an agent selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, 4 amino-2,2,6,6-tetramethylpiperidine-1-oxyl(4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin(everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, or a combination thereof. 
     
     
         23 . The coating of  claim 8 , further comprising an agent selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, 4 amino-2,2,6,6-tetramethylpiperidine-1-oxyl(4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin(everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prodrugs thereof, or a combination thereof. 
     
     
         24 . A method of treating a human being by implanting in the human being an implantable device comprising the coating of  claim 22 ,
 wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.   
     
     
         25 . A method of treating a human being by implanting in the human being an implantable device comprising the coating of  claim 23 ,
 wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.